Skip to content

Study · Case report or series · n = 1 · 2023

3 results

A Case of Dulaglutide-Induced Vaginal Bleed.

Vaccaro CJ, Zaidi SMH, Iskander PA, McFadden E

Cureus9 May 2023Cited by 2 (Europe PMC)

PMID37303364 (opens in a new tab)PMCIDPMC10249759 (opens in a new tab)DOI10.7759/cureus.38774 (opens in a new tab)PepBankPUB-37303364
Download PDFPubMedAsk about this study
Jump to 3 results

Summary

Type 2 diabetes mellitus (T2DM) is a growing challenge across the globe. The disease process is amendable to lifestyle modifications in the early stages. If those changes fail to correct endocrine dysfunction, medical therapy is initiated. Initially, therapy for type 2 diabetes consisted of biguanides and sulfonylureas. With modern medicine, we have developed dipeptidyl peptidase-4 inhibitors, sodium-glucose cotransporter-2 inhibitors, and glucagon-like peptide 1 (GLP-1) receptor agonists. Dulaglutide is a GLP-1 receptor agonist that is sold under the brand name Trulicity. The most common side effect associated with Dulaglutide is gastrointestinal discomfort. We present a case of severe vaginal bleeding due to a rare side effect of Dulaglutide. A 44-year-old perimenopausal female with a past medical history of type 2 diabetes mellitus presented to the clinic after experiencing significant vaginal bleeding. The patient was unable to tolerate Metformin and Semaglutide in the past. The abnormal vaginal hemorrhage started one week after receiving the second dose of Dulaglutide. Her hemoglobin concentration fell significantly. Dulaglutide was immediately discontinued, and her vaginal bleeding stopped. This case documents the necessity of post-market surveillance to oversee the safety of recently approved medications by the Food and Drug Administration (FDA). Rare side effects can emerge in the general population that were not seen during clinical trials. Physicians should consider the possibility of adverse medication reactions when determining whether to start a new medication or a conventional one.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanCase report or seriesSafety outcome

    In a perimenopausal woman with type 2 diabetes, vaginal hemorrhage began one week after the second dulaglutide dose.

    In plain wordsIn one woman with diabetes, vaginal bleeding began one week after the second dulaglutide dose.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    IncreaseVaginal bleeding
    Study

    n = 1

    Outcome group
    Adverse events · Reproductive and sexual health
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The abnormal vaginal hemorrhage started one week after receiving the second dose of Dulaglutide.
    1 context sentence
    Summary · context
    A 44-year-old perimenopausal female with a past medical history of type 2 diabetes mellitus presented to the clinic after experiencing significant vaginal bleeding.
  2. 02HumanCase report or seriesSafety outcome

    In a woman with vaginal hemorrhage after dulaglutide exposure, hemoglobin concentration fell significantly.

    In plain wordsIn one woman with bleeding after dulaglutide exposure, hemoglobin levels fell significantly.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseHemoglobin concentration
    Study

    n = 1

    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Her hemoglobin concentration fell significantly.
    2 context sentences
    Summary · context
    The abnormal vaginal hemorrhage started one week after receiving the second dose of Dulaglutide.
    Summary · context
    A 44-year-old perimenopausal female with a past medical history of type 2 diabetes mellitus presented to the clinic after experiencing significant vaginal bleeding.
  3. 03HumanCase report or seriesSafety outcome

    In a woman with type 2 diabetes, vaginal bleeding stopped after dulaglutide discontinuation.

    In plain wordsIn one woman with diabetes, vaginal bleeding stopped after dulaglutide was discontinued.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseBleeding resolution after discontinuation
    Study

    n = 1

    Outcome group
    Adverse events · Reproductive and sexual health
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Dulaglutide was immediately discontinued, and her vaginal bleeding stopped.
    1 context sentence
    Summary · context
    A 44-year-old perimenopausal female with a past medical history of type 2 diabetes mellitus presented to the clinic after experiencing significant vaginal bleeding.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Versions 4 to 9Current

    28 Oct 2026, 02:03 UTC

    The same notice was added 6 times, first on 22 Oct 2026, 02:26 UTC. The status did not change between them.

    Study results updated

  2. Version 3

    21 Oct 2026, 18:59 UTC

    Study data updated · source update from Europe PMC

  3. Version 2

    11 Oct 2026, 00:50 UTC

    Study results updated

  4. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.